Michael S. Cookson, MD, on darolutamide’s safety profile

Among the various androgen receptor pathway inhibitors in the prostate cancer space, darolutamide (Nubeqa) tolerability profile is frequently cited as a distinguishing feature. Here, Michael S. Cookson, MD, MMHC, FACS, how that profile may influence treatment decisions and patient adherence in the mHSPC setting.

For more prostate cancer content, see: https://www.urologytimes.com/special-report/news-network-prostate-cancer-at-aua-2026

Видео Michael S. Cookson, MD, on darolutamide’s safety profile канала Urology Times